Chronic kidney disease (CKD) represents a major global health burden due to its strong association with cardiovascular morbidity and mortality. Declining glomerular filtration rate (GFR) is not only a marker of renal dysfunction but also an independent predictor of adverse cardiovascular outcomes. This study aimed to evaluate the relationship between GFR decline and major cardiovascular risk factors in patients with CKD. A cross-sectional observational study was conducted involving 180 patients diagnosed with CKD stages 2–4. Clinical, biochemical, and hemodynamic parameters were assessed, including estimated GFR (eGFR), systolic and diastolic blood pressure, lipid profile, C-reactive protein (CRP), and NT-proBNP levels. Statistical analysis was performed using Pearson correlation and multivariate regression models. Results demonstrated a significant inverse correlation between eGFR and systolic blood pressure (r = −0.54, p < 0.001), LDL cholesterol (r = −0.42, p < 0.01), CRP (r = −0.61, p < 0.001), and NT-proBNP (r = −0.65, p < 0.001). Patients with stage 4 CKD exhibited a 2.3-fold higher prevalence of cardiovascular risk markers compared to stage 2 patients. The findings confirm that declining GFR significantly contributes to the progression of cardiovascular risk in CKD patients. Early identification of renal dysfunction and aggressive management of modifiable cardiovascular factors are essential for improving long-term outcomes.

Chronic kidney disease, glomerular filtration rate, cardiovascular risk, CRP

Bikbov, B., Purcell, C. A., Levey, A. S., et al. (2023). Global, regional, and national burden of chronic kidney disease, 1990–2021. The Lancet, 401(10382), 1315–1334. https://doi.org/10.1016/S0140-6736(23)00040-7

Bowe, B., Xie, Y., & Al-Aly, Z. (2020). Acute and post-acute sequelae of chronic kidney disease: Cardiovascular implications. Nature Reviews Nephrology, 16(9), 516–528.

Chen, T. K., Knicely, D. H., & Grams, M. E. (2021). Chronic kidney disease diagnosis and management: A review. JAMA, 325(13), 1296–1309.

Coresh, J., et al. (2021). Estimated glomerular filtration rate and cardiovascular outcomes. Circulation, 143(3), 252–263.

Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., et al. (2020). Chronic kidney disease and cardiovascular risk: Epidemiology and mechanisms. Kidney International, 98(3), 524–536.

Hsu, C. Y., & Powe, N. R. (2022). Recent advances in CKD epidemiology and cardiovascular complications. New England Journal of Medicine, 386(18), 1737–1748.

Jankowski, J., Floege, J., Fliser, D., & Böhm, M. (2021). Cardiovascular disease in chronic kidney disease: Pathophysiological insights. Circulation Research, 128(6), 748–766.

KDIGO. (2021). Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements, 11(1), 1–115.

Matsushita, K., et al. (2020). Measures of chronic kidney disease and risk of cardiovascular disease. The Lancet Diabetes & Endocrinology, 8(7), 585–595.

McCullough, P. A., et al. (2022). Cardiorenal syndrome: Updated pathophysiology and management. Journal of the American College of Cardiology, 79(16), 1589–1605.

Rangaswami, J., et al. (2020). Cardiorenal protection in chronic kidney disease. Journal of the American College of Cardiology, 76(10), 1197–1211.

Rossignol, P., et al. (2022). Biomarkers in chronic kidney disease and cardiovascular risk prediction. European Heart Journal, 43(12), 1103–1116.

van der Velde, M., et al. (2021). Declining GFR and cardiovascular risk in population-based cohorts. Kidney International, 100(5), 1013–1023.

Wanner, C., & Tonelli, M. (2020). KDIGO clinical practice guideline update for CKD and cardiovascular risk. Kidney International Supplements, 10(4), e1–e115.

Yilmaz, M. I., et al. (2023). Inflammation and oxidative stress in CKD progression and cardiovascular disease. Clinical Journal of the American Society of Nephrology, 18(2), 145–157.